improving perinatal outcomes. (D) The extent to which such Federal programs are coordinated across agencies and the identification of opportunities for improved coordination in such Federal programs and activities. . C Innovation 4301. Removing the cap on OTA Section 319L(c)(5)(A)(ii) of the Public Health Service Act (42 U.S.C. 247d–7e(c)(5)(A)(ii)) is amended to read as follows: (ii) Limitations on authority To the maximum extent practicable, competitive procedures shall be used when entering into transactions to carry out projects under this subsection. . 4302. Extending the priority review program for agents that present national security threats Section 565A of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–4a ) is amended by striking subsection (g). 4303. Priority zoonotic animal drugs Chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 et seq.) is amended by inserting after section 512 the following: 512A. Priority zoonotic animal drugs (a) In general The Secretary shall, at the request of the sponsor intending to submit an application for approval of a new animal drug under section 512(b)(1) or an application for conditional approval of a new animal drug under section 571, expedite the development and review of such new animal drug if preliminary clinical evidence indicates that the new animal drug, alone or in combination with 1 or more other animal drugs, has the potential to prevent or treat a zoonotic disease in animals, including a vector borne-disease, that has the potential to cause serious adverse health consequences for, or serious or life-threatening diseases in, humans. (b) Request for designation The sponsor of a new animal drug may request the Secretary to designate a new animal drug described in subsection (a) as a priority zoonotic animal drug. A request for the designation may be made concurrently with, or at any time after, the opening of an investigational new animal drug file under section 512(j) or the filing of an application under section 512(b)(1) or